CN115551842A - 联苯类化合物 - Google Patents

联苯类化合物 Download PDF

Info

Publication number
CN115551842A
CN115551842A CN202180032515.8A CN202180032515A CN115551842A CN 115551842 A CN115551842 A CN 115551842A CN 202180032515 A CN202180032515 A CN 202180032515A CN 115551842 A CN115551842 A CN 115551842A
Authority
CN
China
Prior art keywords
compound
och
pharmaceutically acceptable
compounds
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180032515.8A
Other languages
English (en)
Other versions
CN115551842B (zh
Inventor
廖勇刚
钱文远
林军
韦昌青
胡国平
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN115551842A publication Critical patent/CN115551842A/zh
Application granted granted Critical
Publication of CN115551842B publication Critical patent/CN115551842B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

本发明公开了新的联苯类化合物，具体公开了式(II)所示化合物及其药学上可接受的盐。
Figure DDA0003921374870000011

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202180032515.8A 2020-06-08 2021-06-04 联苯类化合物 Active CN115551842B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010514549 2020-06-08
CN2020105145498 2020-06-08
CN2021105111195 2021-05-11
CN202110511119 2021-05-11
PCT/CN2021/098381 WO2021249305A1 (zh) 2020-06-08 2021-06-04 联苯类化合物

Publications (2)

Publication Number Publication Date
CN115551842A true CN115551842A (zh) 2022-12-30
CN115551842B CN115551842B (zh) 2024-04-23

Family

ID=78845299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032515.8A Active CN115551842B (zh) 2020-06-08 2021-06-04 联苯类化合物

Country Status (2)

Country Link
CN (1) CN115551842B (zh)
WO (1) WO2021249305A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080769A (zh) * 2011-04-13 2014-10-01 Epizyme股份有限公司 芳基或杂芳基取代苯化合物
WO2017174023A1 (zh) * 2016-04-08 2017-10-12 南京明德新药研发股份有限公司 作为ezh2抑制剂的联苯化合物
WO2020020374A1 (zh) * 2018-07-27 2020-01-30 苏州信诺维医药科技有限公司 多取代苯环化合物、制备方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894216A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
US10150764B2 (en) * 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
CN105037360B (zh) * 2014-04-28 2016-08-17 四川大学 吡啶酮衍生物及其制备方法和用途
WO2016140501A1 (en) * 2015-03-04 2016-09-09 Kainos Medicine, Inc. Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
US11214561B2 (en) * 2017-01-25 2022-01-04 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080769A (zh) * 2011-04-13 2014-10-01 Epizyme股份有限公司 芳基或杂芳基取代苯化合物
WO2017174023A1 (zh) * 2016-04-08 2017-10-12 南京明德新药研发股份有限公司 作为ezh2抑制剂的联苯化合物
WO2020020374A1 (zh) * 2018-07-27 2020-01-30 苏州信诺维医药科技有限公司 多取代苯环化合物、制备方法及其用途

Also Published As

Publication number Publication date
CN115551842B (zh) 2024-04-23
WO2021249305A1 (zh) 2021-12-16

Similar Documents

Publication Publication Date Title
US20210017163A1 (en) Hydrochloride salt form for ezh2 inhibition
WO2021068952A1 (zh) 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物
CN107922358A (zh) 1,3,5‑三嗪衍生物及其使用方法
CN114761411B (zh) 作为erk抑制剂的螺环类化合物及其应用
KR102654710B1 (ko) 신규 벤즈이미다졸 화합물 및 그의 의약 용도
JP2023548204A (ja) Ｃｄ７３阻害剤及びその応用
TWI758999B (zh) 作為erk抑制劑的噻唑并內醯胺類化合物及其應用
EP4215523A1 (en) Isochroman compound
WO2019001556A1 (zh) 取代芳基醚类化合物、其制备方法、药用组合物及其应用
EP3181554B1 (en) Quinazoline derivative
US20240025908A1 (en) Compound used as kinase inhibitor and use thereof
JP7214925B2 (ja) Ｐａｎ－ＲＡＦキナーゼ阻害剤としてのビアリール化合物
KR102500569B1 (ko) 선택적 btk 키나제 억제제로서의 피라졸로피리딘계 화합물
CN115551842A (zh) 联苯类化合物
WO2022184119A1 (zh) 酪氨酸激酶抑制剂及其药物应用
CN108419436B (zh) 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
CN109438279B (zh) 一种克服egfr耐药突变的小分子化合物及其制备方法和用途
CN111362924A (zh) 氘代的嘧啶衍生物及其用途
CN112279863A (zh) Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
WO2022028557A1 (zh) 18f标记的联苯类化合物、其中间体、制备方法、药物组合物及应用
JPWO2005121105A1 (ja) 新規３−フェニルテトラヒドロシンノリン−５−オール誘導体及びその医薬用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant